1. Osteoarthritis Guideline Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. American College of Rheumatology [serial online] 2020 [cited 6.01.2020]. Available from URL: https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines.
2.
Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI Guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019; 27(11): 1578–1589, doi: 10.1016/j.joca.2019.06.011.
3.
Sakellariou G, Conaghan PG, Zhang W, et al. EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis Ann Rheum Dis 2017; 76: 1484–1494, doi: 10.1136/annrheumdis-2016-210815.
4.
Babinets LS, Halabitska IM. Chronic inflammatory process and bone tissue changes in patients with osteoarthritis and exocrine pancreatic insufficiency Lekarsky Obzor 2020; 69(1): 7–10.
5.
Вabinets LS, Halabitska IM, Kotsaba YY, et al. The effect of the proteolisis’ system activity for the trophological status of patients with osteoarthritis and exocrine insufficiency of pancreas. Wiad Lek 2018; 71(2 pt 1): 273–276.
6.
Babinets LS, Kytsai KY, Kotsaba YY, et al. Improvement of the complex medical treatment for the patients wіth chronic biliary pancreatitis. Wiad Lek 2017; 70(2): 213–216.
7.
Babinets LS, Halabitska IM. Characteristics of joint pain in patients with primary osteoarthritis and comorbid conditions with exocrine pancreatic insufficiency Lekarsky Obzor 2021; 70(2): 62–64.
8.
Gandek B. Measurement properties of the Western Ontario and McMaster Universities Osteoarthritis Index: a systematic review. Arthritis Care Res (Hoboken) 2015; 67(2): 216–229, doi: 10.1002/acr.22415.
9.
Buranova S, Akhmedov K, Razakova F. The importance of treatment aimed at the dynamics of Cartilage Oligomer Matrix Protein (COMP) in patients with the knee joint osteoarthritis. Am J Med Med Sci 2021; 11(2): 148–153, doi: 10.5923/j.ajmms.20211102.18
10.
Nilsdotter A, Bremander A. Measures of hip function and symptoms: Harris Hip Score (HHS), Hip Disability and Osteoarthritis Outcome Score (HOOS), Oxford Hip Score (OHS), Lequesne Index of Severity for Osteoarthritis of the Hip (LISOH), and American Academy of Orthopedic Surgeons (AAOS) Hip and Knee Questionnaire Review. Arthritis Care Res (Hoboken) 2011; 63 (Suppl. 11): S200–S207, doi: 10.1002/acr.20549.
11.
Kikuchi S, Togo K, Ebata N, et al. Database analysis on the relationships between nonsteroidal anti-inflammatory drug treatment variables and incidence of acute myocardial infarction in Japanese patients with osteoarthritis and chronic low back pain. Adv Ther 2021; 38(3): 1601–1613, doi: 10.1007/s12325-021-01629-6.
12.
Ebata-Kogure N, Murakami A, Nozawa K, et al. Treatment and healthcare cost among patients with hip or knee osteoarthritis: a cross-sectional study using a real-world claims database in Japan between 2013 and 2019. Clin Drug Investig 2020; 40(11): 1071–1084, doi: 10.1007/s40261-020-00968-6.
13.
Leerling AT, Cañete AN, Ramautar AIE, et al. Sternocostoclavicular hyperostosis: positive clinical and radiological response on Pamidronate. Front Endocrinol (Lausanne) 2021; 12, doi: 10.3389/fendo.2021.621604.
14.
Zhao J-L, Liang G-H, Pan J-K, et al. Network meta-analysis of oral Chinese patent medicine in treatment of knee osteoarthritis. Zhongguo Zhongyao Zazhi 2021; 46(4): 981–999, doi: 10.19540/j.cnki.cjcmm.20200721.502.
15.
Pereira D, Peleteiro B, Araújo J, et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 2011; 19(11): 1270–1285, doi: 10.1016/j.joca.2011.08.009.
16.
Leyland KM, Gates LS, Sanchez-Santos MT, et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res 2021; 33(3): 529–545, doi: 10.1007/s40520-020-01762-2.
17.
Maloney J, Pew S, Wie C, et al. Comprehensive review of topical analgesics for chronic pain. Curr Pain Headache Rep 2021; 25(2), doi: 10.1007/s11916-020-00923-2.
18.
Dahlhamer JM, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults – United States, 2016. MMWR 2018; 67(36): 1001–1006, doi: 10.15585/mmwr.mm6736a2.
19.
Parkoohi PI, Amirzadeh K, Mohabbati V, et al. Satisfaction with chronic pain treatment Anesth Pain Med 2015; 5(4), doi: 10.5812/aapm.23528.
20.
Selvanathan J, Pham C, Nagappa M, et al. Cognitive behavioral therapy for insomnia in patients with chronic pain – a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2021; 60, doi: 10.1016/j.smrv.2021.101460.
21.
Mahesh G, Kumar KA, Reddanna P. Overview on the discovery and development of anti-inflammatory drugs: should the focus be on synthesis or degradation of pge2? J Inflamm Res 2021; 4: 253–263, doi: 10.2147/JIR.S278514.
22.
Alimoradian A, Samimi F, Aslfalah H, et al. Piroxicam reduces acute and chronic pain response in type 1 diabetic rats. J Basic Clin Physiol Pharmacol 2021; doi: 10.1515/jbcpp-2019-0367.
23.
Guma A, Akhtar S, Najafzadeh M, et al. Ex vivo/in vitro effects of aspirin and ibuprofen, bulk and nano forms, in peripheral lymphocytes of prostate cancer patients and healthy individuals. Mutat Res 2021; 861–862, doi: 10.1016/j.mrgentox.2020.503306.
24.
Dandah O, Najafzadeh M, Isreb M, et al. Aspirin and ibuprofen, in bulk and nanoforms: effects on DNA damage in peripheral lymphocytes from breast cancer patients and healthy individuals. Mutat Res Genet Toxicol Environ Mutagen 2018; 826: 41–46.
25.
Malmgaard-Clausen NM, Jørgensen OH, Høffner R, et al. No additive clinical or physiological effects of short-term anti-inflammatory treatment to physical rehabilitation in the early phase of human achilles tendinopathy: a randomized controlled trial. Am J Sports Med 2021, doi: 10.1177/0363546521991903.
26.
Sağlık BN, Osmaniye D, Levent S, et al. Design, synthesis and biological assessment of new selective COX-2 inhibitors including methyl sulfonyl moiety. Eur J Med Chem 2021; 209, doi: 10.1016/j.ejmech.2020.112918.
27.
He L, Zhang S, Peng D, et al. Synthesis and evaluations of selective COX-2 inhibitory effects: Benzo[d]thiazol analogs. Bioorg Med Chem Lett 2020; 30(17), doi: 10.1016/j.bmcl.2020.127376.
28.
Metwally NH, Mohamed MS. New imidazolone derivatives comprising a benzoate or sulfonamide moiety as anti-inflammatory and antibacterial inhibitors: design, synthesis, selective COX-2, DHFR and molecular-modeling study. Bioorg Chem 2020; 99, doi: 10.1016/j.bioorg.2019.103438.
29.
Marino F, D’Angelo S, Masala IF, et al. Toxicological considerations in the treatment of axial spondylo-arthritis. Expert Opin Drug Metab Toxicol 2020; 16(8): 663–672, doi: 10.1080/17425255.2020.1783240.
30.
Lio C, Luo J, Shen X, et al. Nardosinanone N suppresses LPS-induced macrophage activation by modulating the Nrf2 pathway and mPGES-1. Biochem Pharmacol 2020; 173, doi: 10.1016/j.bcp.2019.113639.
31.
Choy EHS, Panayi GS. Cytokine pathways and joint inflamation in rheumatoid arthritis. N Engl J Med 2001; 344(12): 907–916, doi: 10.1056/NEJM200103223441207.
32.
Sala A, Proschak E, Steinhilber D, et al. Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade. Biochem Pharmacol 2018; 158: 161–173, doi: 10.1016/j.bcp.2018.10.007.
33.
Ton J, Perry D, Thomas B, et al. [PEER umbrella systematic review of systematic reviews management of osteoarthritis in primary care]. Can Fam Physician 2020; 66(3): E89–E98 (in French).
34.
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet 2019; 393(10182): 1745–1759, doi: 10.1016/S0140-6736(19)30417-9.
35.
Fening NY. Novel NSAIDs. SAJAA 2020; 26(6): S45–S48, doi: 10.36303/SAJAA.2020.26.6.S3.2536.
36.
Yammine P, Moussa D, Ayrouth M, et al. Nanoencapsulation of NSAIDs Naproxen and Ibuprofen. Int J Pharm Sci and Res 2017; 8(8): 3347–3353, doi: 10.13040/IJPSR.0975-8232.8(8).3347-53.
37.
Atkinson TJ, Fudin J, Jahn HL, et al. What’s new in NSAID pharmacotherapy: oral agents to injectables. Pain Med 2013; 14(Suppl. 1): S11–S17, doi: 10.1111/ pme.12278.
38.
Rang HP, Dale MM, Ritter JM, et al. Pharmacology. 5th ed. London: Elsevier Churchill Livingstone; 2003.
39.
Atchison JW, Herndon CM, Rusie E. NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. J Manag Care Pharm 2013; 19(9 Suppl. A): S3–S19, doi: 10.18553/ jmcp.2013.19.s9.1.
40.
Hassib ST, Hassan GS, El-Zaher AA, et al. Synthesis and biological evaluation of new prodrugs of etodolac and tolfenamic acid with reduced ulcerogenic potential. Eur J Pharm Sci 2019; 140: 105101, doi: 10.1016/j. ejps.2019.105101.
41.
Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008; 11(2): 81–110, doi: 10.18433/j3t886.
42.
SASA. South African Acute Pain Guidelines. 2nd ed. Pretoria: Medpharm Publications (Pty) Ltd; 2016.
43.
Peesa JP, Yalavarthi PR, Rasheed A, et al. A perspective review on the role of novel NSAID prodrugs in the management of acute inflammation. J Acute Dis 2016; 5(5): 364–381, doi: 10.1016/j.joad.2016.08.002.
44.
Blackler R, Syer S, Bolla M, et al. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS ONE 2012; 7(4): e35196, doi: 10.1371/journal.pone.0035196.
